

SBF Project Implementation Monitoring Report

Philippines: Second Health System Enhancement to Address and Limit COVID-19 under Asia Pacific Vaccine Access Facility Project (HEAL-2)

1. Project Information

Project ID:	000490	Investment Number:	L0490A
Member:	Philippines	Region:	South-Eastern asia
Sector:	Public Health	Sub-sector:	N/A
AIB Financing Type:	Loan: 300 USD million	Co-financier(s):	Asian Development Bank (lead financier)
E&S category:	C	Borrower:	Government of the Philippines
Red Flags Assigned:	0 (first submission)	Monitoring Regime:	Regular Monitoring
Implementing Agency:	Department of Health		
Project Team Leader:	Mehran Avini		
Project Team Members:	Bernardita Saez, Counsel Calvin Quek, Environmental Specialist Yogesh Malla, Financial Management Specialist Yunlong Liu, Procurement Specialist Chang Tian, Project Assistant		
Completed Site Visits by AIB:	Aug, 2021 August 20-27, 2021: Virtual loan inception mission with the Asian Development Bank (lead financier), the Department of Finance and the Department of Health (the implementing agency)		
Planned Site Visits by AIB:	Feb, 2022 Loan review mission expected in February 2022, virtually. ADB has staff located in the Philippines.		

2. Project Summary and Objectives

This Project is supported under AIB's COVID-19 Crisis Recovery Facility and co-financed with the Asian Development Bank (ADB) for the procurement of vaccines eligible under ADB's Asia Pacific Vaccine Access Facility (APVAX) program. The Project will provide critically needed vaccines to assist the Government of the Philippines in mitigating adverse health, social, and economic impacts caused by the COVID-19 pandemic. The objective is to support the Government of the Philippines for rapid procurement of eligible COVID-19 vaccines for up to 50 million Filipinos (43.8% of the total population) to be vaccinated against COVID-19 by 2024.

3. Key Dates

Approval:	Mar. 25, 2021	Signing:	Mar. 26, 2021
Effective:	May. 10, 2021	Restructured (if any):	
Orig. Closing:	Sep. 30, 2024	Rev. Closing (if any):	

4. Disbursement Summary (million)

Currency:	USD		
a) Committed:	300	b) Cancellation (if any):	
c) Disbursed:	199.44	d) Most recent disbursement: (amount / date)	9.428, Sep. 29, 2021
e) Undisbursed:	100.56	f) Disbursement Ratio(%) ¹ :	66.5

¹ Disbursement Ratio is defined as the volume (i.e. the dollar amount) of total disbursed amount as a percentage of the net committed volume, i.e., $f = c / (a - b)$

5. Project Implementation Update

The project is progressing with the Government of the Philippines' efforts to secure vaccines through bilateral negotiations with vaccine suppliers. The first batch of vaccines procured under this project arrived in June 2021 with regular vaccine deliveries since then.

ADB and AIB are working with the Government in monitoring the implementation.

Components	Physical Progress	Environmental & Social Compliance	Procurement
Procurement of eligible COVID-19 vaccines	As of end of September 2021 under this Project the Department of Health has procured (signed contracts) for approximately 85.5 million doses of COVID-19 vaccines and has taken delivery of just over 37 million doses, with the remaining doses expected to be delivered in 2021.	<p>The Project is classified category C for environment and social aspects. The Department of Health (DOH) entered contract with a 3rd party service provider responsible for the reverse logistics (hauling from designated storage facilities or collection points), treatment and final disposal of immunization wastes.</p> <p>The monitoring framework for COVID-19 vaccination waste management developed by DOH has been reviewed and monitoring results are reported through quarterly Project progress reports.</p> <p>The Gender Action Plan has been reviewed, is in progress and is being adapted to address the expedited procurement progress. Data is being gathered and aggregated by sex. A Project gender specialist on-board.</p>	Vaccine procurement has been through direct supplier agreements between the Government of the Philippines and specific suppliers. The contracts are reviewed by ADB and AIIB, with a no-objection letter is issued by the ADB.

Financial Management:

Two DOH finance staff have been assigned to the Project, and a financial management consultant has been retained to support the team.

6. Status of the Grievance Redress Mechanism (GRM)

Project communication with respect to vaccination has commenced. There is no resettlement or land acquisition as part of this Project. The Project will further develop information material containing objectives, activities, timelines, relevant contact information, and a brief summarizing the Project in simple language and infographics targeting wider audience, including the poor and women. The documents will be made available to the public in print and distributed during outreach activities.

7. Results Monitoring

Details can be found below

Baseline Year: Sep. 1, 2021 End Target Year: Sep. 1, 2024

Project Objective Indicators #1

Up to 110 million doses of COVID-19 vaccines procured and delivered to the country by 2024.

Year	Target	Actual	Others, if any
Sep. 1, 2021	5 m doses	85.5 m doses	Contracts have been signed (procured) for 85.5 million doses of vaccines. 37.2 million doses have been delivered as of the end of September 2021. It is expected that nearly 110 m doses of vaccine will be procured in 2021.
Sep. 1, 2022	40 m doses	N/A	
Sep. 1, 2023	65 m doses	N/A	
Sep. 1, 2024	110 m doses	N/A	

Project Objective Indicators #2

Vaccine Information Management System (VIMS) launched by 2023.

Year	Target	Actual	Others, if any
Sep. 1, 2021	N/A	VIMS implementation has commenced.	Department of Information and Communications Technology (DICT) has worked closely with the National Vaccine Operations Center (NVOC) which is tasked to analyze and report on vaccine supply and inoculation through National Covid-19 Vaccine Dashboard. VIMS in its basic format is in operation and is being further developed with more capabilities. Data is being collected from various sites through existing systems. The system is continually updated. A soft launch took place in April 2021.
Sep. 1, 2022	Launch - with updates to the system.	N/A	

Sep. 1, 2023	Launch the system	N/A	
--------------	-------------------	-----	--

Intermediate Result Indicators #1

Gender- and socially inclusive protocol and guidelines on the deployment and administration of vaccines, addressing the specific needs of marginalized women and women in especially difficult circumstances, developed, approved, and disseminated by 2023.

Year	Target	Actual	Others, if any
Sep. 1, 2021	N/A	Communication by the DOH has commenced.	Gender consultant was mobilized in Q3 2021. The capacity development component has not yet commenced. It will commence in Q4 2021.
Sep. 1, 2022	Gender- and socially inclusive protocol and guidelines	N/A	
Sep. 1, 2023	Gender- and socially inclusive protocol and guidelines	N/A	

Remarks: